<p>阿瑪琳公司（NASDAQ:AMRN - 獲取免費報告）在四月份的空頭頭寸顯著下降。截至四月十五日，空頭頭寸總計 629,400 股，較三月三十一日的 11,970,000 股下降了 94.7%。該公司約有 3.1% 的股票被做空。根據 88,700 股的平均交易量，目前的空頭比例為 7.1 天。</p>
<h2>分析師升級與降級</h2>
<ul>
<li>三隻生物科技股票正在獲得動力</li>
</ul>
<p>AMRN 已成為多份分析師報告的主題。StockNews.com 在四月十六日（星期三）的一份研究報告中開始覆蓋阿瑪琳的股票。他們對該公司給予了 “賣出” 評級。高盛集團在四月十七日（星期四）的研究報告中將阿瑪琳的目標價從 20.00 美元下調至 7.00 美元，並對該公司設定了 “賣出” 評級。</p>
<p><strong>查看我們關於 AMRN 的最新股票報告</strong></p>
<h2>阿瑪琳股票下跌 6.7%</h2>
<ul>
<li>Ocugen 或阿瑪琳是否值得投資的便士股票？</li>
</ul>
<p>NASDAQ:AMRN 的股票在週五交易中下跌了 0.75 美元，達到 10.43 美元。該股票的交易量為 55,645 股，而其平均交易量為 73,755 股。該股票的 50 日簡單移動平均為 9.62 美元，200 日簡單移動平均為 10.39 美元。阿瑪琳的 52 周低點為 7.08 美元，52 周高點為 20.60 美元。該公司的市值為 2.1417 億美元，市盈率為-115.89，貝塔值為 1.38。</p>
<p>阿瑪琳（NASDAQ:AMRN - 獲取免費報告）最後一次公佈財報是在三月十二日（星期三）。這家生物製藥公司報告本季度每股收益為（2.40 美元），低於市場共識預期的（1.20 美元）1.20 美元。阿瑪琳的股本回報率為-7.22%，淨利潤率為-16.33%。該公司本季度的收入為 6231 萬美元，而市場共識預期為 3237 萬美元。分析師平均預測阿瑪琳在當前年度的每股收益為-0.15 美元。</p>
<h2>機構資金流入與流出</h2>
<ul>
<li>阿瑪琳在財報發佈後是否值得加入你的投資組合？</li>
</ul>
<p>一些大型投資者最近調整了他們對 AMRN 的持股。紐約州共同退休基金在第四季度購買了阿瑪琳的新頭寸，價值 68,000 美元。Waterfront Wealth Inc.在第四季度將其在阿瑪琳的持股增加了 181.4%。Waterfront Wealth Inc.現在擁有 2481766 股這家生物製藥公司的股票，價值 1,204,000 美元，此前在該期間又購買了 1,599,956 股。Arkfeld Wealth Strategies L.L.C.在第四季度將其在阿瑪琳的持股增加了 52.6%。Arkfeld Wealth Strategies L.L.C.現在擁有 58,000 股這家生物製藥公司的股票，價值 30,000 美元，此前在上個季度又購買了 20,000 股。LCM Capital Management Inc 在第四季度將其在阿瑪琳的持股增加了 3.1%。LCM Capital Management Inc 現在擁有 838,259 股這家生物製藥公司的股票，價值 407,000 美元，此前在該期間又購買了 25,100 股。最後，Stonepine Capital Management LLC 在第四季度收購了阿瑪琳的新股份，價值約 55,000 美元。目前 22.25% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於阿瑪琳</h2>
<p>（獲取免費報告）</p>
<p>阿瑪琳公司是一家制藥公司，專注於在美國、歐洲國家、加拿大、黎巴嫩和阿拉伯聯合酋長國開發和商業化治療心血管疾病的療法。該公司提供 VASCEPA，這是一種僅限處方的 omega-3 脂肪酸產品，用於作為飲食的輔助治療，以降低嚴重高甘油三酯血癥成年患者的甘油三酯水平。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票而非阿瑪琳</li>
<li>哪些華爾街分析師最準確？</li>
<li>市場認為 Robinhood 的財報可能會推動股票上漲</li>
<li>如何在 7 個步驟中投資大麻股票</li>
<li>Churchill Downs 股票：關税擔憂是否會抑制德比收益？</li>
<li>股票平均計算器</li>
<li>AT&amp;T：用户增長與回購信號看漲反轉</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在阿瑪琳嗎？</h2>
<p>在考慮阿瑪琳之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而阿瑪琳並不在名單上。</p>
<p>雖然阿瑪琳目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

阿瑪琳

<p>阿瑪琳公司（NASDAQ:AMRN）在 4 月 15 日的空頭頭寸大幅下降，下降了 94.7%，降至 629,400 股。這大約佔公司股份的 3.1%。根據 88,700 股的平均交易量，目前的覆蓋天數比率為 7.1 天。分析師給出了 “賣出” 評級，高盛將目標股價從 20.00 美元下調至 7.00 美元。阿瑪琳的股票下跌了 6.7%，交易價格為 10.43 美元，市值為 2.1417 億美元，上一季度的每股收益為負 2.40 美元</p>

<p>Amarin Co. plc (NASDAQ:AMRN - Get Free Report) saw a significant decline in short interest in April. As of April 15th, there was short interest totalling 629,400 shares, a decline of 94.7% from the March 31st total of 11,970,000 shares. Approximately 3.1% of the company's stock are short sold. Based on an average trading volume of 88,700 shares, the short-interest ratio is presently 7.1 days.</p>
<div class="lb-trans"><p>阿瑪琳公司（NASDAQ:AMRN - 獲取免費報告）在四月份的空頭頭寸顯著下降。截至四月十五日，空頭頭寸總計 629,400 股，較三月三十一日的 11,970,000 股下降了 94.7%。該公司約有 3.1% 的股票被做空。根據 88,700 股的平均交易量，目前的空頭比例為 7.1 天。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級與降級</h2>
</div><ul>
<li>3 Biotech Stocks Gaining Momentum</li>
</ul>
<div class="lb-trans"><ul>
<li>三隻生物科技股票正在獲得動力</li>
</ul>
</div><p>AMRN has been the subject of several analyst reports. StockNews.com assumed coverage on shares of Amarin in a research note on Wednesday, April 16th. They issued a &#34;sell&#34; rating for the company. The Goldman Sachs Group reduced their price target on Amarin from $20.00 to $7.00 and set a &#34;sell&#34; rating for the company in a research report on Thursday, April 17th.</p>
<div class="lb-trans"><p>AMRN 已成為多份分析師報告的主題。StockNews.com 在四月十六日（星期三）的一份研究報告中開始覆蓋阿瑪琳的股票。他們對該公司給予了 “賣出” 評級。高盛集團在四月十七日（星期四）的研究報告中將阿瑪琳的目標價從 20.00 美元下調至 7.00 美元，並對該公司設定了 “賣出” 評級。</p>
</div><p><strong>Check Out Our Latest Stock Report on AMRN</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 AMRN 的最新股票報告</strong></p>
</div><h2>Amarin Stock Down 6.7 %</h2>
<div class="lb-trans"><h2>阿瑪琳股票下跌 6.7%</h2>
</div><ul>
<li>Are Ocugen or Amarin Good Penny Stocks to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>Ocugen 或阿瑪琳是否值得投資的便士股票？</li>
</ul>
</div><p>Shares of NASDAQ:AMRN traded down $0.75 during trading on Friday, reaching $10.43. The stock had a trading volume of 55,645 shares, compared to its average volume of 73,755. The stock has a fifty day simple moving average of $9.62 and a two-hundred day simple moving average of $10.39. Amarin has a 52 week low of $7.08 and a 52 week high of $20.60. The firm has a market capitalization of $214.17 million, a price-to-earnings ratio of -115.89 and a beta of 1.38.</p>
<div class="lb-trans"><p>NASDAQ:AMRN 的股票在週五交易中下跌了 0.75 美元，達到 10.43 美元。該股票的交易量為 55,645 股，而其平均交易量為 73,755 股。該股票的 50 日簡單移動平均為 9.62 美元，200 日簡單移動平均為 10.39 美元。阿瑪琳的 52 周低點為 7.08 美元，52 周高點為 20.60 美元。該公司的市值為 2.1417 億美元，市盈率為-115.89，貝塔值為 1.38。</p>
</div><p>Amarin (NASDAQ:AMRN - Get Free Report) last announced its earnings results on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($1.20) by ($1.20). Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%. The firm had revenue of $62.31 million during the quarter, compared to the consensus estimate of $32.37 million. On average, analysts forecast that Amarin will post -0.15 EPS for the current year.</p>
<div class="lb-trans"><p>阿瑪琳（NASDAQ:AMRN - 獲取免費報告）最後一次公佈財報是在三月十二日（星期三）。這家生物製藥公司報告本季度每股收益為（2.40 美元），低於市場共識預期的（1.20 美元）1.20 美元。阿瑪琳的股本回報率為-7.22%，淨利潤率為-16.33%。該公司本季度的收入為 6231 萬美元，而市場共識預期為 3237 萬美元。分析師平均預測阿瑪琳在當前年度的每股收益為-0.15 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入與流出</h2>
</div><ul>
<li>Does Amarin Deserve a Spot in Your Portfolio after Earnings ?</li>
</ul>
<div class="lb-trans"><ul>
<li>阿瑪琳在財報發佈後是否值得加入你的投資組合？</li>
</ul>
</div><p>A number of large investors have recently modified their holdings of AMRN. New York State Common Retirement Fund bought a new position in Amarin during the fourth quarter worth $68,000. Waterfront Wealth Inc. increased its holdings in shares of Amarin by 181.4% during the 4th quarter. Waterfront Wealth Inc. now owns 2,481,766 shares of the biopharmaceutical company's stock worth $1,204,000 after purchasing an additional 1,599,956 shares during the period. Arkfeld Wealth Strategies L.L.C. raised its position in shares of Amarin by 52.6% during the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 20,000 shares during the last quarter. LCM Capital Management Inc lifted its stake in shares of Amarin by 3.1% in the fourth quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company's stock valued at $407,000 after buying an additional 25,100 shares during the period. Finally, Stonepine Capital Management LLC acquired a new stake in Amarin during the fourth quarter worth about $55,000. 22.25% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投資者最近調整了他們對 AMRN 的持股。紐約州共同退休基金在第四季度購買了阿瑪琳的新頭寸，價值 68,000 美元。Waterfront Wealth Inc.在第四季度將其在阿瑪琳的持股增加了 181.4%。Waterfront Wealth Inc.現在擁有 2481766 股這家生物製藥公司的股票，價值 1,204,000 美元，此前在該期間又購買了 1,599,956 股。Arkfeld Wealth Strategies L.L.C.在第四季度將其在阿瑪琳的持股增加了 52.6%。Arkfeld Wealth Strategies L.L.C.現在擁有 58,000 股這家生物製藥公司的股票，價值 30,000 美元，此前在上個季度又購買了 20,000 股。LCM Capital Management Inc 在第四季度將其在阿瑪琳的持股增加了 3.1%。LCM Capital Management Inc 現在擁有 838,259 股這家生物製藥公司的股票，價值 407,000 美元，此前在該期間又購買了 25,100 股。最後，Stonepine Capital Management LLC 在第四季度收購了阿瑪琳的新股份，價值約 55,000 美元。目前 22.25% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Amarin</h2>
<div class="lb-trans"><h2>關於阿瑪琳</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.</p>
<div class="lb-trans"><p>阿瑪琳公司是一家制藥公司，專注於在美國、歐洲國家、加拿大、黎巴嫩和阿拉伯聯合酋長國開發和商業化治療心血管疾病的療法。該公司提供 VASCEPA，這是一種僅限處方的 omega-3 脂肪酸產品，用於作為飲食的輔助治療，以降低嚴重高甘油三酯血癥成年患者的甘油三酯水平。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Amarin</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>Markets Think Robinhood Earnings Could Send the Stock Up</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?</li>
<li>Stock Average Calculator</li>
<li>AT&amp;T: Subscriber Growth &amp; Buybacks Signal Bullish Turnaround</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票而非阿瑪琳</li>
<li>哪些華爾街分析師最準確？</li>
<li>市場認為 Robinhood 的財報可能會推動股票上漲</li>
<li>如何在 7 個步驟中投資大麻股票</li>
<li>Churchill Downs 股票：關税擔憂是否會抑制德比收益？</li>
<li>股票平均計算器</li>
<li>AT&amp;T：用户增長與回購信號看漲反轉</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amarin Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在阿瑪琳嗎？</h2>
</div><p>Before you consider Amarin, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮阿瑪琳之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而阿瑪琳並不在名單上。</p>
</div><p>While Amarin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然阿瑪琳目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

阿瑪琳公司（NASDAQ:AMRN）空頭頭寸最新情況